Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer

被引：0
|
作者：
Braydon Meyer
Samuel Clifton
Warwick Locke
Phuc-Loi Luu
Qian Du
Dilys Lam
Nicola J. Armstrong
Beena Kumar
Niantao Deng
Kate Harvey
Alex Swarbrick
Vinod Ganju
Susan J. Clark
Ruth Pidsley
Clare Stirzaker
机构：
[1] Garvan Institute of Medical Research,Epigenetics Research Laboratory, Genomics and Epigenetics Theme
[2] CSIRO Health and Biosecurity,Molecular Diagnostics Solutions
[3] New South Wales,St. Vincent’s Clinical School
[4] UNSW Australia,Department of Mathematics and Statistics
[5] Curtin University,Cancer Research Theme
[6] Hudson Institute of Medical Research,undefined
[7] Monash Health Pathology,undefined
[8] Monash Health,undefined
[9] Monash University,undefined
[10] Garvan Institute of Medical Research,undefined
来源：
Clinical Epigenetics | 2021年 / 13卷
关键词：
DNA methylation; Methylome; Epigenetics; Triple-negative breast cancer; Neoadjuvant chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient’s response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC.
引用
收藏
相关论文
共 50 条
  • [1] Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
    Meyer, Braydon
    Clifton, Samuel
    Locke, Warwick
    Luu, Phuc-Loi
    Du, Qian
    Lam, Dilys
    Armstrong, Nicola J.
    Kumar, Beena
    Deng, Niantao
    Harvey, Kate
    Swarbrick, Alex
    Ganju, Vinod
    Clark, Susan J.
    Pidsley, Ruth
    Stirzaker, Clare
    [J]. CLINICAL EPIGENETICS, 2021, 13 (01)
  • [2] Development of DNA methylation markers panels for neoadjuvant chemotherapy response prediction in triple-negative breast cancer
    Sigin, V. O.
    Kalinkin, A. I.
    Ignatova, E.
    Chesnokova, G.
    Vinogradov, I. Y.
    Vinogradov, I. I.
    Vinogradov, M. I.
    Strelnikov, V. V.
    Zaletaev, D. V.
    Tanas, A. S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1225 - S1225
  • [3] Tumor Microenvironment Can Predict Chemotherapy Response of Patients with Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
    Kim, Dongjin
    Yu, Yeuni
    Jung, Ki Sun
    Kim, Yun Hak
    Kim, Jae-Joon
    [J]. CANCER RESEARCH AND TREATMENT, 2024, 56 (01): : 162 - 177
  • [4] Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy
    Naoko Matsuda
    Kumiko Kida
    Sachiko Ohde
    Koyu Suzuki
    Hideko Yamauchi
    Seigo Nakamura
    Hiroko Tsunoda
    [J]. Breast Cancer, 2018, 25 : 43 - 49
  • [5] Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy
    Matsuda, Naoko
    Kida, Kumiko
    Ohde, Sachiko
    Suzuki, Koyu
    Yamauchi, Hideko
    Nakamura, Seigo
    Tsunoda, Hiroko
    [J]. BREAST CANCER, 2018, 25 (01) : 43 - 49
  • [6] Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer
    Salvador-Coloma, Carmen
    Santaballa, Ana
    Sanmartin, Elena
    Calvo, David
    Garcia, Ana
    Hervas, David
    Cordon, Lourdes
    Quintas, Guillermo
    Ripoll, Francisco
    Panadero, Joaquin
    Font de Mora, Jaime
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 139 : 119 - 134
  • [7] Using machine learning approaches to predict response to neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Fisher, Timothy Byron
    Li, Hongxiao
    Ts, Rekha
    Krishnamurthy, Jayashree
    Bhattarai, Shristi
    Janssen, Emiel A. M.
    Kong, Jun
    Aneja, Ritu
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [8] DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer
    Sigin, Vladimir O. O.
    Kalinkin, Alexey I. I.
    Nikolaeva, Alexandra F. F.
    Ignatova, Ekaterina O. O.
    Kuznetsova, Ekaterina B. B.
    Chesnokova, Galina G. G.
    Litviakov, Nikolai V. V.
    Tsyganov, Matvey M. M.
    Ibragimova, Marina K. K.
    Vinogradov, Ilya I. I.
    Vinogradov, Maxim I. I.
    Vinogradov, Igor Y. Y.
    Zaletaev, Dmitry V. V.
    Nemtsova, Marina V. V.
    Kutsev, Sergey I. I.
    Tanas, Alexander S. S.
    Strelnikov, Vladimir V. V.
    [J]. CANCERS, 2023, 15 (05)
  • [9] Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Jung, Yoon Yang
    Hyun, Chang Lim
    Jin, Min-Sun
    Park, In Ae
    Chung, Yul Ri
    Shim, Bobae
    Lee, Kyu Ho
    Ryu, Han Suk
    [J]. JOURNAL OF BREAST CANCER, 2016, 19 (03) : 261 - 267
  • [10] The response to neoadjuvant chemotherapy and prognosis of triple-negative breast cancer patients.
    Nakano, E.
    Hojo, T.
    Masumura, K.
    Kikuyama, M.
    Akashi, S.
    Kinoshita, T.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 337S - 337S
12345